Larimar Therapeutics, Inc. Common Stock (LRMR)
PHARMACEUTICAL PREPARATIONS
Larimar Therapeutics, Inc. Common Stock (LRMR) is listed on Nasdaq, where it has traded since May 29, 2020.
- Listed On
- Nasdaq
- Listed Since
- May 29, 2020
- Employees
- 71
- Market Cap
- $319M
About Larimar Therapeutics, Inc. Common Stock
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 157 institutions reported holding LRMR, with 95.0 million shares worth $291.3 million in aggregate. The largest reported holder was Deerfield Management Company,, with 35.6 million shares worth $108.6 million. Of the 5 largest holders listed below, 1 opened a new position in LRMR, 3 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Deerfield Management Company, | 35,606,974 | $109M | Unchanged |
| Blue Owl Capital Holdings | 9,163,157 | $28M | Added 28.7% |
| BlackRock | 5,678,035 | $17M | Added 51.33% |
| Vanguard | 4,865,837 | $15M | Added 34.24% |
| Defilade Capital Management | 3,670,135 | $11M | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is LRMR?
Larimar Therapeutics, Inc. Common Stock (LRMR) is listed on Nasdaq, where it has traded since May 29, 2020.
Who are the largest institutional holders of LRMR?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of LRMR were Deerfield Management Company,, Blue Owl Capital Holdings and BlackRock.
How many institutions own LRMR?
157 institutions reported a position in LRMR for the quarter ended June 30, 2026, worth $291.3 million in total.
Did institutions buy or sell LRMR last quarter?
Of the 5 largest reported holders, 1 opened a new position in LRMR, 3 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for LRMR.
Every reported institutional holder, plus insider and congressional trades in LRMR, on SentiSense.